About Us

Bill Gerhart has more than 20 years of experience building high-performance execution teams to develop new therapeutics for serious diseases. Prior to joining Kinevant in 2021, he was the CEO of Respivant/Patara Pharma, Elevation Pharma, and Mpex Pharma which focused on developing new medicines for pulmonary fibrosis, chronic obstructive pulmonary disease, and cystic fibrosis, respectively. In addition to his biotech activities, Bill serves as the Vice Chair of Sanford Burnham Prebys Institute’s Board of Trustees, a non-profit medical research institute focused on basic and translational research in cancer, neurodegeneration, infectious, and inflammatory diseases.

Bill earned a BA from Baylor University and an MBA from Harvard Business School.

Tuan Nguyen has more than 15 years of experience in biopharma working on small molecules and AAV gene therapies. Most recently, he was VP of Finance at Adverum Biotechnologies. Prior to that he held various senior Finance leadership roles at Intarcia Therapeutics, Fibrogen, and UCB. He has helped raise over $1 billion in dilutive and non dilutive capital. Tuan earned his MBA with dual concentration in Finance and Entrepreneurship, Innovation, & Change from Emory University.

Gary has more than 25 years of experience in Clinical and Commercial biologics and small molecules with increasing levels of leadership. Most recently, Gary was Senior Vice President of Quality at Allakos Inc. Prior to that, his leadership spanned Quality, Regulatory, Drug Safety and Operational Excellence at Theravance Biopharma. Gary also was the Site Head of Quality at Boehringer Ingelheim’s Fremont, California facility and he worked at Genentech for 16 years in roles of increasing responsibility.

Gary graduated from UC Berkeley with a Degree in Integrative Biology and Environmental Science in 1996 and a Masters of Business Administration from St. Mary’s College in 2011. Gary serves as an adjunct professor for the Keck Institute, teaching a Master’s Level course called Pharmaceutical Quality.

Chantal brings more than two decades of experience in biopharma working on small molecules, biologics, and AAV gene therapies from discovery through commercialization. She most recently was Chief of Staff to the Chief Scientific Officer and the Research division at PTC Therapeutics Inc. Prior to that she was the program/alliance management lead at Provention Bio; product development lead at Regenxbio; project leader at Shire and GlaxoSmithKline; and senior investigator at Smithkline Beecham, leading research in the antimicrobial field.

Chantal earned a Ph.D. in microbiology and biochemistry from the University of Nancy, France. She completed post-doctoral training in Canada and the UK, as well as a Certificate in Clinical Trial Management from Temple University.

Cynthia Scott has more than 15 years of regulatory experience working on biologics and small molecules, in the areas of diabetes, oncology, infectious diseases, and rare diseases. Prior to joining Kinevant, Cynthia served as a regulatory consultant for over 10 years where she led cross-functional teams toward global product development goals, providing regulatory strategy and team leadership, ranging from early to late phase development.

Cynthia earned a BS from Eastern Nazarene College and an MS in Drug Regulatory Affairs and Health Policy from Massachusetts College of Pharmacy and Health Sciences.

Rayne has over eleven years of experience in patient advocacy, clinical trial recruitment, data science innovation, and program management.  Prior to Kinevant, Rayne worked with the Muscular Dystrophy Association as the Vice President of MOVR – a unified, national patient data hub for neuromuscular diseases – facilitating research initiatives with pharmaceutical and academic partners.  Before MDA, Rayne led global patient recruitment and advocacy efforts at miRagen Therapeutics across multiple rare hematological malignancies as the Director of Medical and Patient Affairs.  Rayne was also a Program Manager at Takeda where she launched a novel, systematic study of exceptional drug responders to oncology treatments, in collaboration with Harvard Medical School.

Rayne earned a BS in Finance from the University of Florida and an MPH from Emory University.